for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover Journal of Clinical and Experimental Hepatology
  [SJR: 0.283]   [H-I: 7]   [5 followers]  Follow
   Full-text available via subscription Subscription journal
   ISSN (Print) 0973-6883
   Published by Elsevier Homepage  [3175 journals]
  • Direct-Acting Antiviral Agents for HCV Infection
    • Authors: Madhumita Premkumar; Radha K. Dhiman
      Pages: 1 - 2
      Abstract: We have come a long way in the treatment of hepatitis C using the new direct-acting antiviral (DAAs). This issue of Journal of Clinical and Experimental Hepatology (JCEH) covers several new aspects of DAAs in hepatitis C virus (HCV) therapy. With the availability of safety data from pooled trials, pan-genotypic drugs, and availability of cost effective generic drugs, the elimination of HCV is a very real possibility.1,2 There is increasing data on the safety of DAAs in niche groups like post-transplantation, thalassemia and other hematological disorders, co-infections with hepatitis B virus (HBV) / human immunodeficiency virus (HIV), patients on hemodialysis, and the pediatric population.
      Citation: Journal of Clinical and Experimental Hepatology 8, 1 (2018)
      PubDate: 2018-03
      DOI: 10.1016/j.jceh.2018.01.002
      Issue No: Vol. 8, No. 1 (2018)
  • Percutaneous Transhepatic Approach for Recanalization of Superior
           Mesenteric and Portal Vein in a Patient With Pancreatic Neuroendocrine
           Tumor Presenting With Bleeding Duodenal Varices: A Brief Case Report
    • Authors: Ajit Yadav; Gaurav Gangwani, Nitin Mishra, Arun Gupta
      Abstract: Occlusion of Portal Vein (PV) and Superior Mesenteric Vein (SMV) is a known effect of local infiltration by pancreatic or mesenteric neuroendocrine tumors. Venous occlusion leads to formation of collateral pathways to restore hepatopetal flow in main PV and these collateral pathways can be seen in the form of ectopic (duodenal or jejunal) varices. We present a case of bleeding duodenal varices secondary to SMV occlusion by a locally infiltrating pancreatic neuroendocrine tumor which was successfully treated by coil embolization of varices and SMV stenting of the occluded venous segment after failure of endoscopic glue injection.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-04-13
      DOI: 10.1016/j.jceh.2018.03.003
  • Prevalence of Hepatitis B and C Viral Markers in Blood Donors Deferred
           from Donating Blood on the Basis of a History of Jaundice of Unknown
    • Authors: Chandra Prakash; Suchet Sachdev, Neelam Marwaha, Rekha Hans
      Abstract: The aim of the present study was to know the prevalence of viral hepatitis markers among blood donors deferred on the basis of a history of jaundice of unknown origin and to predict the impact of this deferral on blood safety.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-04-13
      DOI: 10.1016/j.jceh.2018.03.001
  • Immune-tolerant Chronic Hepatitis B Infection—Is the Liver Really
    • Authors: Sandeep Satsangi
      Abstract: The Indian National Association for Study of the Liver (INASL) constantly provides Indian consensus guidelines to manage various diseases affecting the liver. The INASL recently published its guidelines to manage patients with Hepatitis B Virus (HBV) infection in your esteemed journal and I would like to congratulate the authors on their commendable work.1
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-04-06
      DOI: 10.1016/j.jceh.2018.03.002
  • Controlled Attenuation Parameter for Assessment of Hepatic Steatosis in
           Indian Patients
    • Authors: Gyanranjan Rout; Saurabh Kedia, Baibaswata Nayak, Rajni Yadav, Prasenjit Das, Subrat K. Acharya, Deepak Gunjan, Vishwajeet Singh, Mousumi Mahanta, Swatantra Gupta, Sandeep Aggarwal, Shalimar
      Abstract: The gold standard method for measurement of hepatic steatosis is liver histology. Controlled Attenuation Parameter (CAP) can measure hepatic steatosis non-invasively. We aimed to assess the accuracy of CAP for detection of hepatic steatosis.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-03-26
      DOI: 10.1016/j.jceh.2018.02.010
  • Outcome of Living Donor Liver Transplantation for Wilson's Disease in
           Adults: A Single Center Experience
    • Authors: Narendra S. Choudhary; Sanjiv Saigal, Neeraj Saraf, Amit Rastogi, Sanjay Goja, Prashant Bhangui, Srinivasan Thiagrajan, Dheeraj Gautam, Deepak Govil, Vijay Vohra, Arvinder S. Soin
      Abstract: Although liver transplantation is a definitive cure for Wilson's disease (WD), there is limited data about results of living donor liver transplantation (LDLT) in adults.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-03-24
      DOI: 10.1016/j.jceh.2017.11.003
  • How to Design a Multicenter Clinical Trial in Hepatic Encephalopathy
    • Authors: Lorenzo Ridola; Silvia Nardelli, Stefania Gioia, Oliviero Riggio
      Abstract: The design of clinical trials on Hepatic Encephalopathy (HE) is not an easy task, in fact there are several issues related to the performance of clinical trials in HE that have impeded progress in the field, mainly because most of the studies on HE therapy were performed before the era of rigorous Randomized Controlled Trials (RCTs). In this review we discuss the major problems affecting previously published trials on HE treatments aiming to provide evidences, suggestions and indications to prepare well designed RCTs in three different settings: (1) management of hospitalized patients with episodic HE; (2) secondary prophylaxis in patients following an episode of HE; and (3) management of minimal/covert HE.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-03-22
      DOI: 10.1016/j.jceh.2018.02.007
  • Long Term Survival of Patients Undergoing TIPS in Budd-Chiari Syndrome
    • Authors: Amey D. Sonavane; Deepak N. Amarapurkar, Krantikumar R. Rathod, Sundeep J. Punamiya
      Abstract: There has been significant improvement in understanding the etiology and management of Budd-Chiari Syndrome (BCS). Patients with chronic or acute-on-chronic BCS need radiological interventions in the form of angioplasty, hepatic vein/inferior vena cava stenting or Transjugular Intrahepatic Portosystemic Shunt (TIPS). Data regarding the long term follow up of patients undergoing TIPS is limited. We thus prospectively followed-up BCS patients who underwent TIPS at our center.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-03-10
      DOI: 10.1016/j.jceh.2018.02.008
  • Structural and Epitope Analysis (T- and B-Cell Epitopes) of Hepatitis C
           Virus (HCV) Glycoproteins: An in silico Approach
    • Authors: Anoop Kumar; Roma Pandey, Inderjit S. Yadav, Mausumi Bharadwaj
      Abstract: Chronic infection with Hepatitis C Virus (HCV) poses a major risk for liver disease like cirrhosis, liver failure and hepatocellular carcinoma. In terms of percentage, the prevalence of HCV in India was found to be low to moderate (1–1.5%), but in terms of sheer numbers, India has a significant number of global HCV patients. Presently, HCV can be treated with direct acting-antibody drugs but there is no prophylactic or therapeutic vaccine available against it. In HCV infection, T- and B-cell immunity is important for clearing the virus.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-03-03
      DOI: 10.1016/j.jceh.2017.12.010
  • Hepatitis B Virus Infection of Normal Hepatic Stem/Progenitor Cells
    • Authors: Wendy W. Bautista; Carla Osiowy, Julianne Klein, Gerald Y. Minuk
      Abstract: Whether the hepatitis B virus (HBV) infects normal hepatic stem/progenitor cells (NSCs) and if so, whether such infections play a role in the pathogenesis of HBV-induced chronic liver disease (CLD) and/or hepatocellular carcinoma (HCC) remains to be determined. The objectives of this study were to determine whether HBV infects NSCs and whether such infections alter NSC activity in a manner likely to contribute to the development of CLD and/or HCC.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-28
      DOI: 10.1016/j.jceh.2018.02.002
  • Prevalence of Nephrolithiasis in Patients with Chronic Liver Disease: A
           Case–Control Study
    • Authors: Ivan E. Porter; William C. Palmer, Alexander S. Parker, David O. Hodge, Nancy N. Diehl, William E. Haley
      Abstract: Nephrolithiasis is known to be associated with several systemic diseases including chronic kidney disease and renal failure, which can also occur as a complication of chronic liver disease (CLD). This study aimed to assess the prevalence of nephrolithiasis in patients with CLD.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-28
      DOI: 10.1016/j.jceh.2018.01.004
  • Hepatitis C Virus Infection and Vaccine Development
    • Authors: Xuan Guo; Jin-Yi Zhong, Jun-Wen Li
      Abstract: In the twenty-seven years since the discovery of hepatitis C virus (HCV) the majority of individuals exposed to HCV establish a persistent infection, which is a leading cause of chronic liver disease, cirrhosis and hepatocellular carcinoma. In developed nations, the cure rates of HCV infection could be over 90% with direct-acting antiviral (DAA) regimens, which has made the great progress in global eradication. However, the cost of these treatments is so expensive that the patients in developing nations, where the disease burden is the most severe, could not afford it, which highly restricted its access.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-27
      DOI: 10.1016/j.jceh.2018.02.003
  • Potential Implications of Detecting HBsAg in Asymptomatic People in an
           Endemic Community Through Medical Camps
    • Authors: Gourdas Choudhuri; Varun Gupta, Tajinder Singh Negi, Rajesh Ojha
      Abstract: In a developing country like India with intermediate level of prevalence of hepatitis B, most of the patients remain undiagnosed as they are asymptomatic. The purpose of the study was to diagnose asymptomatic HBsAg positive patients from the general population and evaluate further the potential clinical implications of IDAHS.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-26
      DOI: 10.1016/j.jceh.2018.02.005
  • Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR)
           in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver
           Disease (NAFLD) as Serological Fibrosis Marker
    • Authors: Özlem Akdoğan; Ayşegül Atak Yücel, Zeynep Gök Sargin, Cemile Sönmez, Güldal Esendağli Yilmaz, Seren Özenirler
      Abstract: Progressive hepatic fibrosis is the main predictor of outcome and prognosis in chronic liver diseases. The importance of the coagulation cascade has been defined in liver fibrosis; however, the role of the fibrinolytic pathway has not been clear yet. We aimed to evaluate the association between the plasma levels of soluble urokinase Plasminogen Activator Receptor (uPAR) and the severity of liver fibrosis in chronic hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD).
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-26
      DOI: 10.1016/j.jceh.2018.02.001
  • The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of
           Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis
    • Authors: Osmanuddin Ahmed; Lisa Liu, Antony Gayed, Amanjit Baadh, Mikin Patel, Jordan Tasse, Ulku Turba, Bulent Arslan
      Abstract: The purpose of this research is to analyze the past and forecast the future prevalence of Hepatitis C Virus (HCV) and Nonalcoholic Steatohepatitis (NASH) and their respective contribution to Hepatocellular Carcinoma (HCC) incidence in the setting of novel anti-viral agents and rising obesity rates in the United States.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-24
      DOI: 10.1016/j.jceh.2018.02.006
  • De Novo Autoimmune Hepatitis After Living Donor Liver Transplantation: A
           Series of 4 Cases
    • Authors: Narendra S. Choudhary; Sanjiv Saigal, Dheeraj Gautam, Neeraj Saraf, Arvinder S. Soin
      Abstract: While Autoimmune Hepatitis (AIH) may recur in patients after liver transplant, an AIH like presentation (positive auto antibodies, raised immunoglobulin G, raised transaminases and histology showing plasma cell rich infiltrate) may also occur in liver transplant recipients who had transplant for some other disease, called De novo Autoimmune Hepatitis (DAIH). A timely diagnosis and treatment can prevent further graft dysfunction. We report 4 cases of DAIH after living donor liver transplantation.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-24
      DOI: 10.1016/j.jceh.2018.02.004
  • Recovery of the Cholangiocytes After Ischemia and Reperfusion Injury:
           Ultra-Structural, Hystological and Molecular Assessment in Rats
    • Authors: Thiago P.A. Aloia; Bruno Cogliati, Janaina M. Monteiro, Anna C.K. Goldberg, Paolo R. de Oliveira Salvalaggio
      Abstract: Ischemia–reperfusion (I/R) injury of the liver is a common area of interest to transplant and hepatic surgery. Nevertheless, most of the current knowledge of I/R of the liver derives from the hepatocyte and little is known of what happens to the cholangiocytes. Herein, we assess the sequence of early events involved in the I/R injury of the cholangiocytes.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-23
      DOI: 10.1016/j.jceh.2018.01.003
  • Hepatitis C Continuum of Care in a Treatment Center in Sub-Saharan Africa
    • Authors: Henry N. Luma; Servais A.F.B. Eloumou, Dominique N. Noah, B. Aude Eyenga, Georges Nko’Ayissi, T. Sylvie Taku, Agnes Malongue, Olivier Donfack-Sontsa, Ivo C. Ditah
      Abstract: Hepatitis C virus (HCV) infection is a major public health challenge in Cameroon with over three million people infected. Government efforts to improve care and treatment are unsatisfactory and need to be assessed. We aimed at studying the several steps along the HCV continuum of care in one of two hepatitis treatment centers in Cameroon.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-03
      DOI: 10.1016/j.jceh.2018.01.001
  • Leucopenia: A Rare Extrahepatic Manifestation of Acute Hepatitis A
    • Authors: Ankur Gupta; Priyanka Jain
      Abstract: Hepatitis A infection is a common cause of viral hepatitis in developing world. It is acquired by feco-oral transmission. Patients usually have self-limited disease with uneventful recovery. Extrahepatic manifestations of acute hepatitis A are uncommon and include rash, arthralgias and other rare ones. Hematologic effects include thrombocytopenia and rarely red cell aplasia and aplastic anemia. We recently came across a case of a young female who presented with prodromal symptoms with isolated leucopenia.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-02-02
      DOI: 10.1016/j.jceh.2017.12.007
  • Biopsy Proven Fibrosis in Non-Alcoholic Fatty Liver Disease: An Analysis
           of Risk Factors
    • Authors: Kaumudee Pattnaik; Pallavi Bhuyan, Ayaskant Singh, Shivaram P. Singh, Preetam Nath, Sanjib Kar, Bijay Misra, Jayashree Rath
      Abstract: Non-alcoholic fatty liver disease (NAFLD) is emerging as an important cause of liver disease in India. NAFLD is characterized by hepatic steatosis in absence of a significant alcohol use or other known liver disease. Non-alcoholic steatohepatitis (NASH) is a progressive form of NAFLD which deserves particular attention because it is more prone for development of fibrosis. Liver biopsy is the gold standard for diagnosis of NASH by evaluating necroinflammatory activity and stages of fibrosis. The aim of the study was to analyze liver biopsy specimens and identify risk factors associated with fibrosis in patients of NAFLD in eastern coastal India.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-22
      DOI: 10.1016/j.jceh.2017.12.008
  • Cefazolin Induced Liver Injury and Hypoprothrombinemia
    • Authors: Ankur Gupta; Anil K. Singh, Khursheed Faridi, Priyanka Jain
      Abstract: We encountered an uncommon adverse effect with cefazolin, a first generation cephalosporin in a young male with medulloblastoma. Cefazolin is a commonly used antibiotic for surgical prophylaxis.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-21
      DOI: 10.1016/j.jceh.2017.12.004
  • Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is
           Related to the Presence of Diabetes Mellitus and Severity of Liver Disease
    • Authors: Ram V. Nampoothiri; Ajay Duseja, Manish Rathi, Swastik Agrawal, Naresh Sachdeva, Manu Mehta, Harpal S. Dhaliwal, Radhakrishan Dhiman, Yogesh Chawla
      Abstract: There is sparse data on the prevalence of renal dysfunction in patients with nonalcoholic fatty liver disease (NAFLD). The aim of the present study was to evaluate the presence of renal dysfunction in patients with NAFLD and correlate it with the severity of liver disease.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-19
      DOI: 10.1016/j.jceh.2017.12.005
  • Incidence and Risk of Gallstone Disease in Gilbert's Syndrome Patients in
           Indian Population
    • Authors: Govardhan Bale; Urmila S. Avanthi, N.Rao Padaki, Mithun Sharma, N.Reddy Duvvur, V.Ravi Kanth Vishnubhotla
      Abstract: Individuals with Gilbert's syndrome (GS) harbor mutations in the UGT1A1 gene and are known to have elevated levels of bilirubin, which enhances the risk for gall stone formation. The aim of this study is to screen Indian patients with GS for the incidence of gall stone disease.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-15
      DOI: 10.1016/j.jceh.2017.12.006
  • INASL Position Statements on Prevention, Diagnosis and Management of
           Hepatitis B Virus Infection in India: The Andaman Statements
    • Authors: Anil Arora; Shivaram P. Singh, Ashish Kumar, Vivek A. Saraswat, Rakesh Aggarwal, Manisha Bangar, Pradip Bhaumik, Harshad Devarbhavi, Radha K. Dhiman, Vinod K. Dixit, Ashish Goel, Bhabadev Goswami, Dharmesh Kapoor, Kaushal Madan, Jimmy Narayan, Sandeep Nijhawan, Gaurav Pandey, Ramesh R. Rai, Manoj K. Sahu, Neeraj Saraf, Shalimar, Thrivikrama Shenoy, Varghese Thomas, Manav Wadhawan, INASL Hepatitis B Taskforce
      Abstract: Hepatitis B virus (HBV) infection is one of the major causes of morbidity, mortality and healthcare expenditure in India. There are no Indian consensus guidelines on prevention, diagnosis and management of HBV infection. The Indian National Association for Study of the Liver (INASL) set up a taskforce on HBV in 2016, with a mandate to develop consensus guidelines for diagnosis and management of HBV infection, relevant to disease patterns and clinical practices in India. The taskforce first identified contentious issues on various aspects of HBV management, which were allotted to individual members of the taskforce who reviewed them in detail.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-09
      DOI: 10.1016/j.jceh.2017.12.001
  • Evaluation of Splenic Stiffness in Patients of Extrahepatic Portal Vein
           Obstruction Using 2D Shear Wave Elastography: Comparison with
           Intra-Operative Portal Pressure
    • Authors: Kumble S. Madhusudhan; Ragini Kilambi, Shalimar, Sujoy Pal, Raju Sharma, Deep N. Srivastava
      Abstract: To compare splenic stiffness (SS) with intra-operative portal pressures (PPs) in patients of extrahepatic portal vein obstruction (EHPVO).
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-04
      DOI: 10.1016/j.jceh.2017.12.002
  • Race and Gradient Difference Are Associated with Increased Risk of Hepatic
           Encephalopathy Hospital Admission After Transjugular Intrahepatic
           Portosystemic Shunt Placement
    • Authors: Michael W. Rowley; Myunghan Choi, Steve Chen, Kevin Hirsch, Anil B. Seetharam
      Abstract: Hepatic encephalopathy (HE) is a well-recognized complication of transjugular intrahepatic portosystemic shunt (TIPS) placement. The aim of this investigation was to evaluate incidence and predictors of post-TIPS HE necessitating hospital admission in a non-clinical trial setting.
      Citation: Journal of Clinical and Experimental Hepatology (2018)
      PubDate: 2018-01-03
      DOI: 10.1016/j.jceh.2017.12.003
  • Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We
           at the End of the Road'
    • Authors: Chalermrat Bunchorntavakul; Robert Mitrani, K. Rajender Reddy
      Abstract: Hepatitis C virus (HCV)-related mixed cryoglobulinemia (MC) is a unique condition with complex pathogenesis that involves HCV antigen-driven B-lymphocyte clonal proliferation and mutagenesis. Clinical spectrum of MC ranges from asymptomatic state to clinically-apparent vasculitis involving multiple organs. In the era of direct-acting antiviral (DAA) therapy, patients with HCV-related MC achieve high rates of viral clearance that is commonly accompanied by an improvement in clinical symptoms as well as immunological profiles.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-21
      DOI: 10.1016/j.jceh.2017.11.012
  • Living Donor Liver Transplantation for Acute on Chronic Liver Failure
           Based on EASL-CLIF Diagnostic Criteria
    • Authors: Abu Bakar H. Bhatti; Faisal S. Dar, Muhammad O. Butt, Eraj Sahaab, Mohammad Salih, Najmul H. Shah, Nusrat Y. Khan, Haseeb H. Zia, Eitzaz U. Khan, Nasir A. Khan
      Abstract: The European association for the study of the liver and chronic liver failure consortium (EASL-CLIF) recently proposed diagnostic criteria for acute on chronic liver failure (ACLF). There is lack of data regarding liver transplant outcomes in ACLF patients based on these criteria. The objective of this study was to determine outcome following living donor liver transplantation (LDLT) in ACLF patients.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-06
      DOI: 10.1016/j.jceh.2017.11.007
  • Impact of Direct Acting Antiviral Drugs in Treatment Naïve HCV Cirrhosis
           on Fibrosis and Severity of Liver Disease: A Real Life Experience from a
           Tertiary Care Center of North India
    • Authors: Gaurav Garg; Vinod K. Dixit, Sunit K. Shukla, Sudhir K. Singh, Shivam Sachan, Anurag Tiwari, Vinod K. Yadav, Dawesh P. Yadav
      Abstract: Treatment of chronic hepatitis C infection with direct-acting antiviral (DAA) drugs has been highly effective, but data regarding benefit in advanced liver disease is relatively scarce in Indian patients. The aim of this study was to determine the effects of DAA in patients with HCV related cirrhosis (compensated/decompensated) who achieved sustained virological response post-therapy at 12 weeks (SVR12).
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-04
      DOI: 10.1016/j.jceh.2017.11.011
  • High Prevalence of Cirrhosis at Initial Presentation Among Safety-Net
           Adults with Chronic Hepatitis B Virus Infection
    • Authors: Elaine Tang; Sharon Torres, Benny Liu, Rachel Baden, Taft Bhuket, Robert J. Wong
      Abstract: Delays in diagnosis of chronic hepatitis B virus infection (HBV) may be more common among underserved safety-net populations, contributing to more advanced disease at presentation. We aim to evaluate rates of and predictors of cirrhosis and cirrhosis-related complications among adults with chronic HBV.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-03
      DOI: 10.1016/j.jceh.2017.11.009
  • Patient Acceptance of Lactulose Varies Between Indian and American
           Cohorts: Implications for Comparing and Designing Global Hepatic
           Encephalopathy Trials
    • Authors: Sahaj Rathi; Andrew Fagan, James B. Wade, Madhu Chopra, Melanie B. White, Dinesh Ganapathy, Chathur Acharya, Radha K. Dhiman, Jasmohan S. Bajaj
      Abstract: Lactulose is the first-line drug for hepatic encephalopathy (HE), but its acceptance widely differs between Western and Eastern studies. Patient preference for lactulose between different parts of the world has not been examined systematically.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-02
      DOI: 10.1016/j.jceh.2017.11.010
  • A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial
           of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely
           Decompensated Cirrhosis
    • Authors: Gautam Mehta; Sam Rousell, Gary Burgess, Mark Morris, Gavin Wright, Stuart McPherson, Catherine Frenette, Matthew Cave, David T. Hagerty, Alfred Spada, Rajiv Jalan
      Abstract: Cirrhosis and acute-on-chronic liver failure (ACLF) are associated with systemic inflammation, and caspase-mediated hepatocyte cell death. Emricasan is a novel, pan-caspase inhibitor. Aims of this study were to assess the pharmacokinetics, pharmacodynamics, safety and clinical outcomes of emricasan in acute decompensation (AD) of cirrhosis.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-12-01
      DOI: 10.1016/j.jceh.2017.11.006
  • Acute on Chronic Liver Failure—In-Hospital Predictors of Mortality
           in ICU
    • Authors: Sujay Kulkarni; Mithun Sharma, Padaki N. Rao, Rajesh Gupta, Duvvuru N. Reddy
      Abstract: We studied in-hospital predictors of mortality of acute on chronic liver failure (ACLF) in Indian patients.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-30
      DOI: 10.1016/j.jceh.2017.11.008
  • A 4-Week-old Neonate with Jaundice and Hepatosplenomegaly
    • Authors: Geok C. Tan; Melissa Stalling, Bonita Fung
      Abstract: This is a 4-week-old girl born prematurely at 35 weeks gestation to a 15-year-old G1P0 mother after an uncomplicated pregnancy. There is a history of consanguinity. She had jaundice at birth and was treated with phototherapy but it did not resolve. Her development was appropriate for age. At follow-up, she was found to have direct hyperbilirubinemia, hepatomegaly, mild splenomegaly and a suspicious liver lesion on ultrasound. A liver biopsy was performed. Figure 1 provided shows the hepatic parenchyma stained by H&E (A), Periodic Acid Schiff (PAS) with diastase digestion (B) and CD163 (an activated macrophage marker) (C), and a figure of transmission electron microscopy of the liver (D).
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-30
      DOI: 10.1016/j.jceh.2017.11.004
  • Portal Hypertension in a Patient With Recurrent Pancreatic Cancer After
           Radiotherapy and Systemic Chemotherapy
    • Authors: Xingshun Qi; Ji Feng, Xiaodong Shao, Ying Xu, Hongyu Li, Xiaozhong Guo
      Abstract: Portal hypertension secondary to pancreatic cancer is rare in everyday clinical practice.1 The potential mechanism of disease should be portal and splenic vein involvement from pancreatic cancer. This abnormality is also termed as sinistral or left-sided portal hypertension presenting with isolated gastric varices, splenomegaly, and normal liver function. Notably, portal hypertension related complications are often the initial clinical presentations at the diagnosis of pancreatic cancer.2 However, to the best of our knowledge, few studies reported the dynamic evolution of portal hypertension after non-surgical treatment of pancreatic cancer.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-22
      DOI: 10.1016/j.jceh.2017.11.005
  • Endoscopic Cyanoacrylate Glue Injection in Management of Gastric Variceal
           Bleeding: US Tertiary Care Center Experience
    • Authors: Subhash Chandra; Adrian Holm, Rami G. El Abiad, Henning Gerke
      Abstract: Although endoscopic cyanoacrylate glue injection (ECGI) is recommended as first-line treatment for bleeding gastric varices (GV) there is still limited experience with this method in the US. Our aim was to analyze our 10-year experience of ECGI for treatment and prophylaxis of gastric variceal bleeding.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-22
      DOI: 10.1016/j.jceh.2017.11.002
  • Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With
           End Stage Renal Disease on Hemodialysis: A Single Center Experience from
    • Authors: Ankur Gupta; Puneet Arora, Priyanka Jain
      Abstract: Hepatitis C infection is known to increase the morbidity in patients with end stage renal disease (ESRD). Interferon based treatment is poorly tolerated and has limited cure rates in these patients. In limited available data, sofosbuvir based regimens have been shown to have favorable outcomes in these patients.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-20
  • Ideal Cure for Hepatitis B Infection: The Target is in Sight
    • Authors: Shrihari A. Anikhindi; Ashish Kumar, Praveen Sharma, Vikas Singla, Naresh Bansal, Anil Arora
      Abstract: Hepatitis B virus (HBV) is one of the most common causes of liver cirrhosis and hepatocellular carcinoma. Despite recent strides in pharmacotherapy, complete cure of HBV infection still remains an enigma. The biggest obstacle in HBV therapy is clearance of covalently closed circular deoxyribonucleic acid (cccDNA). We discuss about the role of cccDNA in HBV life cycle, efficacy and shortcomings of currently available antivirals as well as promising novel targets to achieve ideal HBV cure.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-11-16
  • Diagnostic Value of Glypican3, Heat Shock Protein 70 and Glutamine
           Synthetase in Hepatocellular Carcinoma Arising in Cirrhotic and
           Non-Cirrhotic Livers
    • Authors: Preithy Uthamalingam; Ashim Das, Arunanshu Behra, Naveen Kalra, Yogesh Chawla
      Abstract: Histopathological distinction of various nodular lesions in liver with sufficient sensitivity and specificity is a challenge even in an expert set up. The panel of immunohistochemical markers composed of glutamine synthetase (GS), Glypican3 (GPC3) and heat shock protein 70 (HSP70) was recommended by the International Consensus Group for Hepatocellular Neoplasia group for the differentiation of high grade dysplastic nodule and early hepatocellular carcinoma (HCC). The panel has been extensively validated in the western population.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-26
      DOI: 10.1016/j.jceh.2017.09.005
  • Upper Gastrointestinal Bleed Due to Invasive Hepatocellular Carcinoma and
           Hepato-Gastric Fistula
    • Authors: Abhijith Bale; Shiran Shetty, Anurag Shetty, Girisha Balaraju, Cannanore Ganesh Pai
      Abstract: A 69-year-old man with cirrhosis of the liver, possibly secondary to nonalcoholic fatty liver disease (NAFLD) and multifocal hepatocellular carcinoma (HCC) post three sessions of transcatheter arterial chemoembolization (TACE) in the past 8 months presented with upper gastrointestinal (UGI) bleed. The last session of TACE was performed two months prior to the presentation. After initial hemodynamic resuscitation an UGI endoscopy was performed which showed a large antral opening at the lesser curvature of the stomach, 3–4cm proximal to the pylorus with an ulcer at its mouth (Figure 1).
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-21
      DOI: 10.1016/j.jceh.2017.09.006
  • Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration: A New Modality
           to Diagnose Peritoneal Tuberculosis in Presence of Decompensated
           Cirrhosis—A Case Series and Review of Literature
    • Authors: Ravi Daswani; Ashish Kumar, Vikas Singla, Gagandeep Kaur, Praveen Sharma, Naresh Bansal, Anil Arora
      Abstract: The gold-standard for diagnosis is growth of Mycobacterium tuberculosis on ascitic fluid or peritoneal culture. Due to the non-specific signs and symptoms of disease, its early diagnosis is difficult, especially in patients with decompensated cirrhosis. The reported sensitivity of ascitic fluid is low and to obtain tissue for peritoneal biopsy in patients with cirrhosis is difficult. Endoscopic ultrasound (EUS) guided fine needle aspiration (FNA) is a good alternative to obtain peritoneal tissue for establishing the diagnosis of peritoneal TB.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-19
      DOI: 10.1016/j.jceh.2017.09.007
  • A Tale Of Two Diseases Or A Story Of Co-Existence: Are Obese
           Individuals’ Immune To Alcoholic Liver Disease'
    • Authors: Ankur Gupta
      Abstract: I read with interest the article by Mehta et al. in recent issue of the journal and wish to congratulate the authors for their study.1 This study may have implications in management of obese patients with alcoholic liver disease (ALD).
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-14
      DOI: 10.1016/j.jceh.2017.09.002
  • Prevalence and Impact of Bacterial Infections in Children With Liver
           Disease—A Prospective Study
    • Authors: Rishi Bolia; Anshu Srivastava, Rungmei Marak, Surender K. Yachha, Ujjal Poddar
      Abstract: Risk of infections is increased in patients with acute liver failure (ALF) and decompensated chronic liver disease (DCLD). We evaluated the frequency, site, type and risk-factors for bacterial infections in children with ALF and DCLD and its effect on outcome.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-10-07
      DOI: 10.1016/j.jceh.2017.08.007
  • Acute Exacerbation Of Autoimmune Hepatitis Mimicking Acute Viral
           Hepatitis—A Case Series and Review of Literature
    • Authors: Sunil Taneja; Pramod Kumar, Suvradeep Mitra, Ajay Duseja, Ranjana Minz, Ashim Das, Radha K. Dhiman, Yogesh Chawla
      Abstract: Acute exacerbation of autoimmune hepatitis (AIH) poses a significant challenge for diagnosis as it can mimic acute viral hepatitis especially in absence of autoantibodies and hypergammaglobulinemia.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-09-21
      DOI: 10.1016/j.jceh.2017.08.005
  • A Case of Acute-On-Chronic Liver Failure (ACLF) Due To An Uncommon Acute
           And Chronic Event
    • Authors: Swastik Agrawal; Baldev S. Rana, Suvradeep Mitra, Ajay Duseja, Ashim Das, Radha K. Dhiman, Yogesh Chawla
      Abstract: Acute on chronic liver failure (ACLF) is an acute worsening of patients with chronic liver disease resulting in liver failure. Usually these patients have cirrhosis as the underlying liver disease with alcohol being the most common etiology. Common hepatitic illnesses causing acute worsening in Indian patients of ACLF include alcoholic hepatitis, acute viral hepatitis related to hepatitis E virus and acute flare in chronic hepatitis B. We report an adult case of ACLF due acute viral hepatitis related to hepatitis A virus infection superimposed on nonalcoholic steatohepatitis without cirrhosis.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-09-10
      DOI: 10.1016/j.jceh.2017.08.006
  • Efficacy And Safety of Sofosbuvir Based Regimens For Treatment of
           Hepatitis C Recurrence After Living Donor Liver Transplantation: An
           Experience From India
    • Authors: Narendra S. Choudhary; Sanjiv Saigal, Dheeraj Gautam, Neeraj Saraf, Amit Rastogi, Sanjay Goja, Prashant Bhangui, Arvinder S. Soin
      Abstract: Results of Sofosbuvir based regimens for hepatitis C (HCV) recurrence after liver transplantation are available from well-designed clinical trials. Most of the data is from deceased donor liver transplant (DDLT) setting, and data on “real world” experience for HCV recurrence after living donor liver transplantation (LDLT) is limited.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-09-08
      DOI: 10.1016/j.jceh.2017.08.004
  • Circulating Fibroblast Growth Factor 19 in Portal and Systemic Blood
    • Authors: Helene Johansson; Lisa-Mari Mörk, Meng Li, Anita L. Sandblom, Ingemar Björkhem, Jonas Höijer, Bo-Göran Ericzon, Carl Jorns, Stefan Gilg, Ernesto Sparrelid, Bengt Isaksson, Greg Nowak, Ewa Ellis
      Abstract: Bile acid homeostasis is essential and imbalance may lead to liver damage and liver failure. The bile acid induced intestinal factor fibroblast growth factor 19 (FGF19) has been identified as a key protein for mediating negative feedback inhibition of bile acid synthesis. The aim of the study was to define FGF19 and bile acid concentrations in portal and systemic blood in the fasted and postprandial state. We also addressed the question if physiological portal levels of FGF19 can be extrapolated from the concentration in systemic blood.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-08-09
      DOI: 10.1016/j.jceh.2017.07.001
  • Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus
           Infection in Patients with β-Thalassemia Major
    • Authors: Rajiv Mehta; Mayank Kabrawala, Subhash Nandwani, Pankaj Desai, Vishwa Bhayani, Sanjay Patel, Viral Parekh
      Abstract: β-thalassemia major patients are susceptible to hepatitis C virus (HCV) infection owing to life-long dependency for blood-transfusion. Moreover, this patient population is at risk of progression of liver fibrosis or development of cirrhosis as a consequence of both iron overload and HCV infection. Hence, this study was carried out to evaluate efficacy and safety of the combination regimen of sofosbuvir and daclatasvir for HCV infection in β-thalassemia major patients.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-07-14
      DOI: 10.1016/j.jceh.2017.06.002
  • Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4
           Patients: Promising Effect on Liver Fibrosis
    • Authors: Asmaa M. Abdel-Aziz; Mohamed A. Ibrahim, Azza A. El-Sheikh, Maha Y. Kamel, Nagwa M. Zenhom, Salam Abdel-Raheim, Hisham Abdelhaleem
      Abstract: The effect of sofosbuvir and daclatasvir in treatment of genotype 4 hepatitis C (HCV) virus is not well documented. This study investigated the safety and efficacy of sofosbuvir plus daclatasvir with or without ribavirin in treatment of HCV genotype 4 patients. The impact of therapy on liver fibrosis as well as the role of IL18 polymorphism in therapeutic outcome was assessed.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-07-07
      DOI: 10.1016/j.jceh.2017.06.006
  • Increased Incidence of Post-transplant Lymphoproliferative Disorder in
           Autoimmune Liver Disease: An Irish National Experience
    • Authors: Ahmed Abu-Shanab; Yasser Ged, Naeem Ullah, Diarmaid Houlihan, Aiden McCormick
      Abstract: Post-transplant lymphoproliferative disorder (PTLD) is a well-recognized complication post solid organs transplant. PTLD represents a broad spectrum of abnormalities ranging from an infectious mononucleosis like illness to malignant lymphoma.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-07-06
      DOI: 10.1016/j.jceh.2017.05.209
  • Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy
           in Patients With Cirrhosis of Liver
    • Authors: Abhijith Bale; C. Ganesh Pai, Shiran Shetty, Girisha Balaraju, Anurag Shetty
      Abstract: Minimal hepatic encephalopathy (MHE), though highly prevalent, is a frequently underdiagnosed complication of cirrhosis of the liver. Because lack of time is reported as the major reason for non-testing, identifying patients at high risk of MHE would help in targeting them for screening. We aimed to determine the factors associated with MHE to help identify patient subgroups with a higher risk of MHE for targeted screening.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-07-01
      DOI: 10.1016/j.jceh.2017.06.005
  • Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C
           Genotypes 1, 3 and 4: A Real Life Experience from India
    • Authors: Varun Mehta; Ramit Mahajan, Vandana Midha, Vikram Narang, Kirandeep Kaur, Arshdeep Singh, Anand Malhotra, Aslam Parvez, Ajit Sood
      Abstract: To assess impact of direct acting antiviral (DAA) therapies for treatment of hepatitis C virus (HCV) genotypes 1, 3 and 4 in a real-world cohort from India.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-07-01
      DOI: 10.1016/j.jceh.2017.06.003
  • Living Donor Liver Transplantation Using Small-for-Size Grafts: Does Size
           Really Matter'
    • Authors: Pulkit Sethi; Manoj Thillai, Binoj Sivasankarapillai Thankamonyamma, Shweta Mallick, Unnikrishnan Gopalakrishnan, Dinesh Balakrishnan, Ramachandran Narayana Menon, Sudhindran Surendran, Puneet Dhar, Sudheer Othiyil Vayoth
      Abstract: In living donor liver transplantation (LDLT), graft-to-recipient weight ratio (GRWR)>0.8% is perceived as the critical graft size. This lower limit of GRWR (0.8%) has been challenged over the last decade owing to the surgical refinements, especially related to inflow and outflow modulation techniques. Our aim was to compare the recipient outcome in small-for-size (GRWR0.8) and to determine the risk factors for mortality when small-for-size grafts (SFSG) were used.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-06-27
      DOI: 10.1016/j.jceh.2017.06.004
  • Natural History of Cirrhosis of Liver after First Decompensation: A
           Prospective Study in India
    • Authors: Apurva S. Shah; Deepak N. Amarapurkar
      Abstract: As liver cirrhosis is a dynamic condition, it is possible to improve survival in decompensated cirrhosis. Hence, we planned a prospective study to determine the natural history of cirrhosis after first decompensation.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-06-26
      DOI: 10.1016/j.jceh.2017.06.001
  • Role of Indocyanine Green in Predicting Post-Transarterial
           Chemoembolization Liver Failure in Hepatocellular Carcinoma
    • Authors: Shalimar; Sushil Jain, Shivanand R. Gamanagatti, Saurabh Kedia, Bhaskar Thakur, Baibaswata Nayak, Harpreet Kaur, Deepak Gunjan, Shashi B. Paul, Subrat K. Acharya
      Abstract: Post-transarterial chemoembolization (TACE) liver failure (LF) is common in patients with hepatocellular carcinoma (HCC). No definitive objective parameters predict its occurrence. We assessed the role of indocyanine green (ICG) in prediction of post-TACE LF.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-06-16
      DOI: 10.1016/j.jceh.2017.05.012
  • Role of Glutathione S Transferase M1 and T1 Gene Polymorphism in Hepatitis
           B Related Liver Diseases and Cryptogenic Cirrhosis
    • Authors: Siddharth Kapahtia; Rajib K. Hazam, Mohammad Asim, Vijay K. Karra, Soumya J. Chowdhury, Bhudev C. Das, Premashis Kar
      Abstract: Progression of hepatitis B virus infection (HBV) might be affected by host genetic factors. The present study was undertaken to study the role of glutathione S-transferases (GST)-M1 and T1 gene polymorphisms in different stages of HBV infection: HBV inactive carrier, chronic hepatitis B and cirrhosis, and cryptogenic cirrhosis.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-06-11
      DOI: 10.1016/j.jceh.2017.05.208
  • Bone Health and Impact of Tenofovir Treatment in Men with Hepatitis-B
           Related Chronic Liver Disease
    • Authors: Kattiparambil G. Sajith; Nitin Kapoor, Sahana Shetty, Ashish Goel, Uday Zachariah, Chundamannil E. Eapen, Thomas V. Paul
      Abstract: Chronic liver disease (CLD) has been shown to have an adverse impact on bone health. Hepatitis-B related CLD and its treatment with tenofovir may have additional effects on skeleton.
      Citation: Journal of Clinical and Experimental Hepatology (2017)
      PubDate: 2017-05-26
      DOI: 10.1016/j.jceh.2017.05.009
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
Home (Search)
Subjects A-Z
Publishers A-Z
Your IP address:
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-